DNA methyltransferase inhibitors were similarly touted as a promising class of therapeutic candidates for tackling pancreatic cancer, as induction of NF-kB inflammatory signaling in pancreatic cancer stem cells requires DNA methylation of the promoter region of SOX9, a critical gene for cancer metastasis (Sun et al., 2013). Here, NFKB1 is linked to pancreatic neoplasm.